Single-Cancer Blood Early Detection Service

Comprehensive service for discovering and identifying new cancer biomarkers in human serum and plasma samples to advance precision medicine and diagnostics.

A high-throughput drug sensitivity testing platform utilizing renewable primary cancer cells to predict treatment response. This service enables personalized treatment selection through comprehensive chemotherapy and targeted drug profiling.

Detection service offering laboratory analysis and diagnostic testing for clinical specimens. Supports medical institutions and healthcare providers with accurate pathology and biomarker identification. Enables timely disease diagnosis and treatment monitoring through specialized analytical protocols.

Precision diagnostic service utilizing liquid biopsy technology for early detection and monitoring of malignant tumors. Analyzes circulating biomarkers from patient blood samples. Enables non-invasive assessment of tumor characteristics and treatment response.

Advanced molecular diagnostic testing service for genetic and molecular-level analysis of diseases. The service enables precise diagnosis and personalized treatment approaches.

A diagnostic service utilizing independently developed CTC (circulating tumor cells) and ctDNA (circulating tumor DNA) detection platforms with high sensitivity and specificity. Compared to traditional detection methods, it can identify more disease information to achieve individualized precision therapy for tumor patients. Liquid biopsy is minimally invasive and painless, providing comprehensive tumor-related information from a single blood sample, offering strong support for malignant tumor diagnosis and treatment as a complement to traditional tissue biopsy.

HCCscreen is a cancer early detection technology and service based on circulating free DNA (cfDNA) and blood biomarkers for hepatocellular carcinoma screening. Clinical data from 1,615 asymptomatic individuals demonstrated 88% sensitivity and 93% specificity, outperforming ultrasound screening which showed 71% sensitivity and 95% specificity. The service is available through hospital networks, government screening programs, physical examination centers, and online health platforms.

High-throughput sequencing detection service for tumor-derived circulating free DNA genetic mutations, enabling precise tumor profiling and monitoring. The service has passed national inter-laboratory quality assessments with full marks.

Molecular testing service for monitoring deep response in chronic myeloid leukemia patients from diagnosis through treatment follow-up. Utilizes genomic sequencing and variant analysis to track disease progression and treatment effectiveness.

A diagnostic service for prenatal screening and diagnosis, focusing on molecular detection techniques for maternal and fetal health assessment.

Multi-biomarker screening solution for early-stage cancer identification. Analyzes blood samples to detect cancer-associated molecular signatures. Facilitates timely clinical intervention and improved patient outcomes.

A blood test designed to improve cancer care equity through accessible screening. It detects cancer biomarkers to support early diagnosis and treatment planning.